UNSPSC 51111803: Estramustine

This classification denotes a tubulin binding agent and nitrogen mustard compound with the molecular formula C23H31Cl2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 35LT29625A, chemically known as 17-hydroxyestra-1,3,5(10)-trien-3-yl bis(2-chloroethyl)carbamate but generally known as estramustine, which bears US NIH Compound Identifier 18140. European Medicines Agency schedules Estramustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07246MIG.

UNSPSC 51111803 Estramustine, a Commodity code, covers pharmaceutical products procured by state and local health systems and cooperative purchasing alliances for distribution across participating facilities. The recent activity under this code reflects state and multistate cooperative purchasing organizations procuring generic and branded pharmaceuticals through structured RFP processes that require vendors to supply products through established wholesale distribution channels, maintain cGMP and DSCSA compliance, carry substantial insurance coverage, and offer flexible pricing models tied to standardized pharmaceutical pricing benchmarks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. Vendors must partner with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), submit detailed product information keyed to National Drug Codes, and commit to available pricing structures including flat price, net price formats, or WAC-minus arrangements. Evaluation weighted price competitiveness at 75 percent, with secondary criteria addressing fixed pricing, administrative fee compliance, EDI capability, and a mandatory 3 percent administrative fee on all purchases. The contract term is two years for new responders with optional extensions, and incumbent responders' amendments extend through June 30, 2028. Products must be available in the marketplace by May 15, 2026, with awards taking effect July 1, 2026, and vendors face performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.